Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), OnKure ...

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Telix Pharmaceuticals (TLPPF – Research Report), Mer...

Analysts’ Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Mereo Biopharma Group Plc (MREO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Solventum Corporation (SOLV – Research Report) and Praxis Precisi...

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Dexcom (DXCM)

Praxis Precision Medicines ( ($PRAX) ) just unveiled an update. On January 6, 2026, Praxis Precision Medicines entered into an underwriting agreeme...

Praxis Precision Medicines Announces Major Underwritten Equity Offering

In a report released yesterday, Kambiz Yazdi from BTIG maintained a Buy rating on Praxis Precision Medicines, with a price target of $843.00. The c...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$309.59	+0.16%	378.28K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$309.59	+0.2%	378.28K
3
4
5
6

PRAX

PRAX

Dividend Overview

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel